Shanghai Allist Pharmaceuticals Co. Ltd. A - Asset Resilience Ratio
Shanghai Allist Pharmaceuticals Co. Ltd. A (688578) has an Asset Resilience Ratio of 21.11% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2019–2025)
This chart shows how Shanghai Allist Pharmaceuticals Co. Ltd. A's Asset Resilience Ratio has changed over time. See how financially flexible is Shanghai Allist Pharmaceuticals Co. Ltd. to measure the company's free cash flow as a share of total liabilities.
Liquid Assets Composition Over Time
This chart breaks down Shanghai Allist Pharmaceuticals Co. Ltd. A's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see how much is Shanghai Allist Pharmaceuticals Co. Ltd. worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥1.81 Billion | 21.11% |
| Total Liquid Assets | CN¥1.81 Billion | 21.11% |
Asset Resilience Insights
- Good Liquidity Position: Shanghai Allist Pharmaceuticals Co. Ltd. A maintains a healthy 21.11% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Shanghai Allist Pharmaceuticals Co. Ltd. A Industry Peers by Asset Resilience Ratio
Compare Shanghai Allist Pharmaceuticals Co. Ltd. A's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 10.93% |
|
Immunitybio Inc
NASDAQ:IBRX |
Biotechnology | 38.07% |
|
Sk Biopharmaceuticals Co Ltd
KO:326030 |
Biotechnology | 0.14% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
R&G PharmaStudies Co. Ltd. A
SHE:301333 |
Biotechnology | 23.94% |
|
Jiangsu Aidea Pharmaceutical Co Ltd
SHG:688488 |
Biotechnology | 4.35% |
|
Zhejiang Shouxiangu Pharm Co
SHG:603896 |
Biotechnology | 12.69% |
|
Jiangsu Bioperfectus Technologies Co Ltd
SHG:688399 |
Biotechnology | 37.23% |
Annual Asset Resilience Ratio for Shanghai Allist Pharmaceuticals Co. Ltd. A (2019–2025)
The table below shows the annual Asset Resilience Ratio data for Shanghai Allist Pharmaceuticals Co. Ltd. A.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 31.77% | CN¥2.51 Billion ≈ $367.44 Million |
CN¥7.90 Billion ≈ $1.16 Billion |
-14.87pp |
| 2024-12-31 | 46.64% | CN¥2.76 Billion ≈ $403.77 Million |
CN¥5.92 Billion ≈ $865.72 Million |
+37.05pp |
| 2023-12-31 | 9.59% | CN¥419.60 Million ≈ $61.40 Million |
CN¥4.38 Billion ≈ $640.42 Million |
-35.93pp |
| 2022-12-31 | 45.52% | CN¥1.57 Billion ≈ $229.27 Million |
CN¥3.44 Billion ≈ $503.70 Million |
-6.38pp |
| 2021-12-31 | 51.90% | CN¥1.62 Billion ≈ $237.74 Million |
CN¥3.13 Billion ≈ $458.06 Million |
-22.60pp |
| 2020-12-31 | 74.50% | CN¥2.23 Billion ≈ $325.66 Million |
CN¥2.99 Billion ≈ $437.10 Million |
+32.77pp |
| 2019-12-31 | 41.73% | CN¥554.40 Million ≈ $81.13 Million |
CN¥1.33 Billion ≈ $194.39 Million |
-- |
About Shanghai Allist Pharmaceuticals Co. Ltd. A
Shanghai Allist Pharmaceuticals Co., Ltd., a pharmaceutical company, engages in the research and development of tumor-targeted drugs in China in internationally. The company's lead product is vometinib mesylate tablet for the treatment of patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer (NSCLC). It also develops pralatinib capsules, as well as glerexyl c… Read more